Total Payments
$8,188
2024 Payments
$267.63
Companies
37
Transactions
401
Medicare Patients
9,847
Medicare Billing
$2.0M
Payment Breakdown by Category
Food & Beverage$7,966 (97.3%)
Other$200.00 (2.4%)
Education$22.34 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,966 | 396 | 97.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $200.00 | 1 | 2.4% |
| Education | $22.34 | 4 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,377 | 89 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,040 | 24 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $945.83 | 79 | $0 (2023) |
| Novo Nordisk Inc | $527.78 | 32 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $450.21 | 21 | $0 (2024) |
| PFIZER INC. | $367.76 | 20 | $0 (2024) |
| Merck Sharp & Dohme LLC | $359.53 | 23 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $297.19 | 12 | $0 (2020) |
| Amgen Inc. | $259.54 | 13 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $214.13 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $267.63 | 14 | PFIZER INC. ($59.98) |
| 2023 | $736.44 | 27 | AbbVie Inc. ($123.92) |
| 2022 | $794.55 | 35 | Novartis Pharmaceuticals Corporation ($170.26) |
| 2021 | $699.28 | 35 | Vifor Pharma, Inc. ($200.00) |
| 2020 | $407.19 | 23 | Janssen Pharmaceuticals, Inc ($179.12) |
| 2019 | $1,954 | 101 | E.R. Squibb & Sons, L.L.C. ($418.62) |
| 2018 | $1,899 | 88 | E.R. Squibb & Sons, L.L.C. ($311.22) |
| 2017 | $1,430 | 78 | E.R. Squibb & Sons, L.L.C. ($273.92) |
All Payment Transactions
401 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/29/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/21/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/31/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $21.68 | General |
| 07/03/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $17.03 | General |
| 06/14/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/06/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $24.71 | General |
| Category: Cardiovascular | ||||||
| 05/07/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.23 | General |
| Category: DIABETES | ||||||
| 04/10/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $21.54 | General |
| 03/27/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.93 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/20/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Diabetes | ||||||
| 03/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GLYXAMBI (Drug), TRADJENTA, JARDIANCE | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: DIABETES | ||||||
| 02/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/21/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/31/2023 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $21.95 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 10/26/2023 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/18/2023 | AbbVie Inc. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $123.92 | General |
| Category: NEUROSCIENCE | ||||||
| 10/10/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $26.56 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/03/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/21/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: DIABETES | ||||||
| 09/20/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $112.95 | General |
| Category: KRYSTEXXA | ||||||
| 09/14/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/28/2023 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 08/24/2023 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,380 | 3,127 | $1.2M | $441,820 |
| 2022 | 16 | 2,350 | 3,105 | $1.3M | $457,446 |
| 2021 | 17 | 2,510 | 3,357 | $1.4M | $521,906 |
| 2020 | 21 | 2,607 | 3,479 | $1.5M | $539,708 |
Total Patients
9,847
Total Services
13,068
Medicare Billing
$2.0M
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 124 | 124 | $350,920 | $166,802 | 47.5% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 124 | 126 | $197,600 | $77,783 | 39.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 273 | 402 | $112,560 | $40,490 | 36.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 204 | 207 | $128,034 | $32,730 | 25.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 330 | 440 | $88,000 | $30,917 | 35.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 124 | 496 | $86,800 | $21,098 | 24.3% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Office | 2023 | 122 | 122 | $48,800 | $19,350 | 39.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 107 | 107 | $39,055 | $14,470 | 37.1% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 238 | 240 | $79,680 | $13,266 | 16.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 131 | 131 | $32,095 | $11,480 | 35.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 480 | 600 | $63,000 | $7,023 | 11.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 19 | $7,410 | $2,741 | 37.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $5,280 | $2,010 | 38.1% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 53 | 56 | $2,970 | $1,152 | 38.8% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 22 | 22 | $1,100 | $207.12 | 18.8% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Office | 2023 | 11 | 12 | $1,364 | $167.65 | 12.3% |
| 93225 | Electrocardiogram (ecg) 2-day continuous | Office | 2023 | 11 | 12 | $1,644 | $133.43 | 8.1% |
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2022 | 127 | 127 | $359,410 | $171,187 | 47.6% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2022 | 128 | 129 | $204,800 | $80,310 | 39.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 256 | 264 | $165,000 | $43,838 | 26.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 246 | 369 | $103,320 | $37,203 | 36.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 296 | 401 | $80,200 | $28,190 | 35.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 128 | 512 | $89,600 | $24,735 | 27.6% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Office | 2022 | 119 | 119 | $47,600 | $18,894 | 39.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 250 | 253 | $83,996 | $15,025 | 17.9% |
About Dr. Ronald Sher, M.D
Dr. Ronald Sher, M.D is a Cardiovascular Disease healthcare provider based in Reisterstown, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447211586.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronald Sher, M.D has received a total of $8,188 in payments from pharmaceutical and medical device companies, with $267.63 received in 2024. These payments were reported across 401 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($7,966).
As a Medicare-enrolled provider, Sher has provided services to 9,847 Medicare beneficiaries, totaling 13,068 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Reisterstown, MD
- Active Since 03/29/2006
- Last Updated 12/04/2020
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1447211586
Products in Payments
- ELIQUIS (Drug) $1,243
- ENTRESTO (Drug) $1,180
- XARELTO (Drug) $844.96
- Ozempic (Drug) $247.74
- JARDIANCE (Drug) $234.20
- Veltassa (Drug) $200.00
- LEQVIO (Drug) $196.88
- VERQUVO (Drug) $186.93
- PRALUENT ALIROCUMAB INJECTION (Biological) $184.04
- PRALUENT (Drug) $166.96
- NEXLETOL (Drug) $144.37
- Vascepa (Drug) $128.97
- QULIPTA (Drug) $123.92
- FREESTYLE LIBRE (Device) $121.82
- INCRUSE (Drug) $118.84
- Tresiba (Drug) $117.17
- KRYSTEXXA (Biological) $112.95
- CHANTIX (Drug) $107.66
- FARXIGA (Drug) $107.29
- WATCHMAN (Device) $106.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.